Pain management is a broad branch of medical science that utilizes an interdisciplinary approach to easing the patient's suffering and enhancing the quality of life of patients with chronic pain. A common aim of pain management is reducing the use of narcotics or pain killers, relaxing the patients' lifestyle and providing education on stress and pain management. The use of pain management treatments in combination with a holistic approach to disease prevention and therapy is now recognized as an effective treatment approach for moderate to severe pain. Chronic pain can result from injury, disease or injury, or be the result of a disease such as cancer or Parkinson's disease.
Market Dynamics:
R&D of new therapeutics is expected to propel growth of the global pain management therapeutics market over the forecast period. For instance, in August 2021, Flexion Therapeutics, Inc. expanded the placebo-controlled trial of FX301, a novel formulation of a locally administered NaV1.7 inhibitor (funapide) which aims to provide at least three to five days of post-operative pain relief while preserving motor function, in patients undergoing bunionectomy.
Moreover, increasing number of pain management clinics is also expected to aid in growth of the market. For instance, in August 2021, QC Kinetix, a regenerative medicine company that offers a non-surgical alternative to pain relief, started a new location Birmingham.
Key features of the study:
- This report provides in-depth analysis of the global pain management therapeutics market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global pain management therapeutics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include AcelRx Pharmaceuticals, Inc. Averitas Pharma, Inc., AmerisourceBergen, Cardinal Health, McKesson Corporation, Johnson & Johnson, Teva Pharmaceuticals, Abbott Laboratories, Allergan, Inc., Covidien plc, Durect Corporation, Eli Lilly and Company, Endo Health Solutions, Inc., Forest Laboratories, Inc., GlaxoSmithKline plc, Hospira, Inc., Merck & Co., Inc., Mundipharma International Ltd., and Novartis International AG
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global pain management therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pain management therapeutics market
Detailed Segmentation:
- Global Pain Management Therapeutics Market, By Pain Type:
- Global Pain Management Therapeutics Market, By Drug Class:
- Global Pain Management Therapeutics Market, By Region:
- North America
- By Pain Type
- By Drug Class
- NSAIDS
- Anesthetics
- Anticonvulsant
- Anti-migraine Drugs
- Antidepressant Drugs
- Opioids
- Non-narcotics
- Analgesics
- By Indication
- Arthritic Pain
- Neuropathic Pain
- Cancer Pain
- Chronic Pain
- Post-operative Pain
- Migraine
- Fibromyalgia
- Bone Fracture
- Muscle Sprain/Strain
- Acute Appendicitis
- Others
- By Country
- Latin America
- By Pain Type
- By Drug Class
- NSAIDS
- Anesthetics
- Anticonvulsant
- Anti-migraine Drugs
- Antidepressant Drugs
- Opioids
- Non-narcotics
- Analgesics
- By Indication
- Arthritic Pain
- Neuropathic Pain
- Cancer Pain
- Chronic Pain
- Post-operative Pain
- Migraine
- Fibromyalgia
- Bone Fracture
- Muscle Sprain/Strain
- Acute Appendicitis
- Others
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Pain Type
- By Drug Class
- NSAIDS
- Anesthetics
- Anticonvulsant
- Anti-migraine Drugs
- Antidepressant Drugs
- Opioids
- Non-narcotics
- Analgesics
- By Indication
- Arthritic Pain
- Neuropathic Pain
- Cancer Pain
- Chronic Pain
- Post-operative Pain
- Migraine
- Fibromyalgia
- Bone Fracture
- Muscle Sprain/Strain
- Acute Appendicitis
- Others
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Pain Type
- By Drug Class
- NSAIDS
- Anesthetics
- Anticonvulsant
- Anti-migraine Drugs
- Antidepressant Drugs
- Opioids
- Non-narcotics
- Analgesics
- By Indication
- Arthritic Pain
- Neuropathic Pain
- Cancer Pain
- Chronic Pain
- Post-operative Pain
- Migraine
- Fibromyalgia
- Bone Fracture
- Muscle Sprain/Strain
- Acute Appendicitis
- Others
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Pain Type
- By Drug Class
- NSAIDS
- Anesthetics
- Anticonvulsant
- Anti-migraine Drugs
- Antidepressant Drugs
- Opioids
- Non-narcotics
- Analgesics
- By Indication
- Arthritic Pain
- Neuropathic Pain
- Cancer Pain
- Chronic Pain
- Post-operative Pain
- Migraine
- Fibromyalgia
- Bone Fracture
- Muscle Sprain/Strain
- Acute Appendicitis
- Others
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Pain Type
- By Drug Class
- NSAIDS
- Anesthetics
- Anticonvulsant
- Anti-migraine Drugs
- Antidepressant Drugs
- Opioids
- Non-narcotics
- Analgesics
- By Indication
- Arthritic Pain
- Neuropathic Pain
- Cancer Pain
- Chronic Pain
- Post-operative Pain
- Migraine
- Fibromyalgia
- Bone Fracture
- Muscle Sprain/Strain
- Acute Appendicitis
- Others
- By Country/Region
- South Africa
- Central Africa
- North Africa
- Company Profiles
- AcelRx Pharmaceuticals, Inc.*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Averitas Pharma, Inc.
- AmerisourceBergen
- Cardinal Health
- McKesson Corporation
- Johnson & Johnson
- Teva Pharmaceuticals
- Abbott Laboratories
- Allergan, Inc
- Covidien plc
- Durect Corporation
- Eli Lilly and Company
- Endo Health Solutions, Inc
- Forest Laboratories, Inc.
- GlaxoSmithKline plc
- Hospira, Inc.
- Merck & Co., Inc
- Mundipharma International Ltd.
- Novartis International AG
“*” marked represents similar segmentation in other categories in the respective section.